Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2003-10-23
2009-06-09
Flood, Michele (Department: 1655)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S217000, C435S216000
Reexamination Certificate
active
07544500
ABSTRACT:
Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.
REFERENCES:
patent: 3434929 (1969-03-01), Buck et al.
patent: 3950513 (1976-04-01), Jensen
patent: 4082612 (1978-04-01), Robbins et al.
patent: 4115551 (1978-09-01), Lormeau et al.
patent: 4177262 (1979-12-01), Lormeau et al.
patent: 4259448 (1981-03-01), Nakamura et al.
patent: 4361652 (1982-11-01), Uemura et al.
patent: 4361653 (1982-11-01), Watanabe et al.
patent: 4442213 (1984-04-01), Heber et al.
patent: 4446316 (1984-05-01), Chazov et al.
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: 4499073 (1985-02-01), Tenold
patent: 4663146 (1987-05-01), Morser et al.
patent: 4774087 (1988-09-01), Wu et al.
patent: 4908204 (1990-03-01), Robinson et al.
patent: 5024829 (1991-06-01), Berger et al.
patent: 5096637 (1992-03-01), DiLeo et al.
patent: 5165912 (1992-11-01), Selmer et al.
patent: 5237050 (1993-08-01), Boyle et al.
patent: 5288489 (1994-02-01), Reich et al.
patent: 5290692 (1994-03-01), Suzuki et al.
patent: 5304383 (1994-04-01), Eibl et al.
patent: 5328996 (1994-07-01), Boyle
patent: 5407673 (1995-04-01), Reich et al.
patent: 5472692 (1995-12-01), Liu et al.
patent: 5728674 (1998-03-01), Sprecher et al.
patent: 5767269 (1998-06-01), Hirsh et al.
patent: 5776452 (1998-07-01), Eibl et al.
patent: 5879923 (1999-03-01), Yago et al.
patent: 6139819 (2000-10-01), Unger et al.
patent: 6207066 (2001-03-01), Trese et al.
patent: 6479253 (2002-11-01), Silver et al.
patent: 1 167 823 (1997-12-01), None
patent: 0256836 (1987-08-01), None
patent: 0 399 321 (1990-11-01), None
patent: 904478 (1962-08-01), None
patent: 2 090 599 (1982-07-01), None
patent: 0207 8633 (1990-03-01), None
patent: 09 065895 (1997-03-01), None
patent: 103 682 (1991-12-01), None
patent: WO 87/06836 (1987-11-01), None
patent: WO 93/15189 (1993-08-01), None
patent: WO 95 04077 (1995-02-01), None
patent: WO 97/15572 (1997-05-01), None
patent: WO 98/37086 (1998-08-01), None
http://www.lakesidepress.com/pulmonary/books/physiology/chap7—1.htm, Chapter 7: Acid-Base Balance.
Kline, D.L., “The Purification and Crystallization of Plasminogen (Profibrinolysin),”Journal of Biological Chemistry, 204: 949-955 (1953).
Supplementary Partial European Search Report (EP 00 99 1956, dated Dec. 17, 2004).
Binder, B.R., et al., “Purification and Characterization of Human Vascular Plasminogen Activator Derived from Blood Vessel Perfusates,”Journal of Biological Chemistry, 254(6): 1998-2003 (1979).
Castellino, F.J., et al., “Rabbit Plasminogen and Plasmin Isozymes,”Methods in Enzymology, 45: 273-286 (1976).
Robbins, K.C., et al., “Human Plasminogen and Plasmin,”Methods in Enzymology, 19: 184-199 (1970).
International Search Report (PCT/US03/34020, dated Jul. 27, 2004).
European Supplementary Partial Search Report (EP 00 97 8572, dated Jul. 16, 2004).
European Supplementary Partial Search Report (EP 00 99 1956, dated Jun. 1, 2004).
European Supplementary Partial Search Report (EP 00 99 0910, dated May 25, 2004).
Ambrus, C., et al., “Insolubilized Activators of the Fibrinolysin System,”J. Med.3: 270-281 (1972).
Ambrus, J.L., et al., “Clinical Pharmacology of various types of fibrinolytic enzyme preparations,”Am. J. Cardiol., 6:462-475 (1960).
Amris, C.J., et al., “Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with Cancer,”Danish Medical Bulletin, 11(5): 141-145 (1964).
Amris, C.J., et al., “Turnover and Distribution of131I-Labelled Procine Plasmin in Man and Dog,”Danish Medical Bulletin,11(5): 146-152 (1964).
Anlyan, W., et al., “Experiences with Fibrinolysin in Peripheral Vascular Occlusive Disease,”Am. J. Cardiol., 6: 507-512 (1960).
Barrett, A.J., et al., “The Electrophoretically ‘Slow’ and ‘Fast’ Forms of the α2-Macroglobulin Molecule,”Biochem. J., 181: 401-418 (1979).
Boucek, R., et al., “Segmental Perfusion of the Coronary Arteries with Fibrinolysin in Man Following a Myocardial Infarction,”Am. J. Cardiol., 6: 525-533 (1960).
Boyles, P.W., et al., “Comparative effectiveness of intravenous and intra-arterial fibrinolysin therapy,”Am. J. Cardiol., 6: 439-446 (1960).
Castellino, F.J. and J.R. Powell, “Human Plasminogen,”Meth. Enzymology, 80: 365-378 (1981).
Collen, D., et al., “Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration,”J. of Clin. Invest., 71(2): 368-376 (1983).
Deutsch, D.G. and E.T. Mertz, “Plasminogen: purification from human plasma by affinity chromatography,”Science 170: 1095-1096 (1970).
Freitag, H., et al., “Lys-plasminogen as an Adjunct to Local Intra-arterial Fibrinolysis of Carotid Territory Stroke: Laboratory and Clinical Findings,”Neuroradiology, 38: 181-185 (1996).
Hedner, U., et al., “Effects of Porcine Plasmin on the Coagulation and Fibrinolytic Systems in Humans,”Blood, 51(1): 157-164 (1978).
Kitamoto, Y., et al., “A Femoral Vein Catheter with Immobilized Urokinase (UKFC) as an Antithrombotic Blood Access,”Trans. Am. Soc. Artif. Intern. Organs, 33: 136-139 (1987).
Larsen, V., “Fibrinolytic Enzyme in the Treatment of Patients with Cancer,”Danish Medical Bulletin, 2(5): 137-140 (1964).
Larson, V., et al., “Fibrinolytic Treatment with Activator-Free Porcine Plasmin,”Scand. J. Clin. Invest. 18(Suppl. 89): 34-73 (1966).
Lijnen, H.R., et al., “Activation of plasminogen by pro-urokinase,”J. Biol. Chem., 261(1): 1253-1258 (1986).
Lippschutz, E.L., et al., “Controlled study of the treatment of coronary occulsion with urokinase-activated human plasmin,”Am. J. Cardiol., 16 :93-98 (1965).
Moser, K., “Effects of Intravenous Administration of Fibrinolysin (Plasmin) in Man,”Circulation, 20: 42-55 (1959).
Mizutani et al. “Potential thrombolysis under selective infusion of autolotous plasmin (AP) solution,”Japanese Heart Journal, 30(5): 723-732 (1989).
Nilsson, T. and B. Wiman, “On the structure of the stable complex between plasmin and alpha-2-antiplasmin,”FEBS Lett., 142(1): 111-114 (1982).
Novokhatny, V. et al. “Thrombolytic potential of locally delivered active plasmin (Pm): In vitro assessment and in vivo comparison with tPA in the rabbit jugular vein trombosis model,”Blood, J. of the Am. Soc. of Hematology, 92(10) Suppl. 2, Abstract 3400. (Nov. 15, 1998).
Robbins, K.C. and L. Summaria, “Plasminogen and Plasmin,”Meth. Enzymol.45:257-273 (1976).
Robbins, K.C., et al., Purification of human plasminogen and plasmin by gel filtration on Sephadex and chromatography on Diethylaminoethyl-Sephadex,The Journal of Biological Chemistry, 238(3): 952-962 (1963).
Sherry, S., “The Origin of Thrombolytic Therapy,”J. Am. Coll. Cardiol., 14(4): 1085-1092 (1989).
Verstraete, M., “The Fibrinolytic System: from Petri Dishes to Genetic Engineering,”Thrombosis and Haemostasis, 74(1): 25-35 (1995).
Wiman, B., “Affinity-chromatographic purification of human alpha 2-antiplasmin,”Biochem. J., 191(1): 229-232 (1980).
Alkjaersig, N., et al., “The Activation of Human Plasminogen,”J. Biol. Chem., 233(1): 81-85 (1958).
Alkjaersig, N., et al., “The Mechanism of Clot Dissolution by Plasmin,”J. Clin. Inves
Bradley Rita T.
Cook Scott A.
Dadd Christopher A.
Kent Jonathan D.
Korneyeva Marina N.
Flood Michele
Talecris Biotherapeutics, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Process for the production of a reversibly inactive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the production of a reversibly inactive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the production of a reversibly inactive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147377